Mixed Response to Ipilimumab in a Melanoma Patient with Brain Metastases: Case Report and Review of the Literature

Management of patients suffering from metastatic malignant melanoma and brain metastasis remains challenging in routine clinical practice. The inhibitory anti-CTLA-4 antibody ipilimumab has recently been approved as second-line therapeutic option for melanoma patients. Increasing evidence suggests d...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldmann, Georg, Brossart, Peter, Zipfel, Matthias, von Lilienfeld-Toal, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: April, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656679/
https://www.ncbi.nlm.nih.gov/pubmed/23687494
http://dx.doi.org/10.1159/000351125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656679/
https://www.ncbi.nlm.nih.gov/pubmed/23687494
http://dx.doi.org/10.1159/000351125

Ejemplares similares